Skip to content
DataLookout
Menu

NCT07911579

A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

DLT
Timeframe: From Day 1 to Day 28
Frequency and severity of AE
Timeframe: From Day 1 to 12 months.
Maximal tolerable dose (MTD)
Timeframe: From Day 1 to 12 months.
Recommended phase 2 dose (RP2D)
Timeframe: From Day 1 to 12 months.
ORR
Timeframe: From Day 1 to 12 months.

Secondary (5)

Cmax
AUCss,
ORR
PFS
OS

Arms and interventions

SYH2051 in combination with Irinotecan Hydrochloride Liposome.Experimental

Drugs: SYH2051, Irinotecan Hydrochloride Liposome.

Sites

1 site in 1 country

  • Tianjin Medical University Cancer Institute & HospitalTianjin, Tianjin Municipality, China